DBS are suitable for 1,5-anhydroglucitol monitoring in GSD1b and G6PC3-deficient patients taking SGLT2 inhibitors to treat neutropenia

Glucosylsphingosine (Lyso-Gb1) as a reliable biomarker in Gaucher disease: a narrative review

(2023) Gaetano Giuffrida et al.   Orphanet Journal of Rare Diseases

Current understanding on pathogenesis and effective treatment of glycogen storage disease type Ib with empagliflozin: new insights coming from diabetes for its potential implications in other metabolic disorders

(2023) Arianna Maiorana et al.   Frontiers in Endocrinology

SGLT5 is the renal transporter for 1,5-anhydroglucitol, a major player in two rare forms of neutropenia

(2023) Jennifer Diederich et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Efficacy and safety of empagliflozin in glycogen storage disease type Ib: Data from an international questionnaire

(2022) Sarah C. Grünert et al.   GENETICS IN MEDICINE

Successful use of empagliflozin to treat neutropenia in two G6PC3 ‐deficient children: Impact of a mutation in SGLT5

(2022) Cécile Boulanger et al.   JOURNAL OF INHERITED METABOLIC DISEASE

Understanding the role of SGLT2 inhibitors in glycogen storage disease type Ib: the experience of one UK centre

(2022) Rebecca K. Halligan et al.   Orphanet Journal of Rare Diseases

The overall benefits of empagliflozin treatment in adult siblings with glycogen storage disease type Ib: one year experience

(2022) Joanna Bidiuk et al.   Archives of Medical Science

SLGT2 Inhibitor Rescues Myelopoiesis in G6PC3 Deficiency

(2022) Prashant Hiwarkar et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Empagliflozin restores neutropenia and neutrophil dysfunction in a young patient with severe congenital neutropenia type 4

(2022) Zsigmond Lédeczi et al.   Journal of Allergy and Clinical Immunology-In Practice

Oral SGLT2 Inhibitors in Glycogen Storage Disease Type Ib and G6PC3-Deficiency. Preliminary Results from an Off-Label Study of 21 Patients

(2022) Jean Donadieu et al.   BLOOD

Empagliflozin in Patients with Chronic Kidney Disease

(2022)   NEW ENGLAND JOURNAL OF MEDICINE

Favorable outcome of empagliflozin treatment in two pediatric glycogen storage disease type 1b patients

(2022) Zufit Hexner-Erlichman et al.   Frontiers in Pediatrics

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

(2021) Stefan D. Anker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treating neutropenia and neutrophil dysfunction in glycogen storage disease IB with an SGLT2-inhibitor

(2020) Saskia B Wortmann et al.   BLOOD

Dried blood spot versus venous blood sampling for phenylalanine and tyrosine

(2020) Kimber van Vliet et al.   Orphanet Journal of Rare Diseases

Review of methods for detecting glycemic disorders

(2020) Michael Bergman et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Failure to eliminate a phosphorylated glucose analog leads to neutropenia in patients with G6PT and G6PC3 deficiency

(2019) Maria Veiga-da-Cunha et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Practical Guide to Prescribing Sodium-Glucose Cotransporter 2 Inhibitors for Cardiologists

(2019) Orly Vardeny et al.   JACC-Heart Failure

Whole-genome sequencing identifies common-to-rare variants associated with human blood metabolites

(2017) Tao Long et al.   NATURE GENETICS

1,5-Anhydroglucitol as a Useful Marker for Assessing Short-Term Glycemic Excursions in Type 1 Diabetes

(2015) Hannah Seok et al.   Diabetes & Metabolism Journal

Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus

(2013) L. H. Chen et al.   DIABETES OBESITY & METABOLISM

SGLT2 inhibition — a novel strategy for diabetes treatment

(2010) Edward C. Chao et al.   NATURE REVIEWS DRUG DISCOVERY

A Syndrome with Congenital Neutropenia and Mutations inG6PC3

(2009) Kaan Boztug et al.   NEW ENGLAND JOURNAL OF MEDICINE

1,5-anhydroglucitol (GlycoMark™) as a marker of short-term glycemic control and glycemic excursions

(2007) Kathleen M Dungan   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS